Previous 10 | Next 10 |
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19 th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET. The conference will be he...
Image source: The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q2 2021 Earnings Call Aug 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Deciphera Pharmaceuticals, inc (DCPH) Q2 2021 Earnings Call T...
Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2021 Earnings Conference Call August 3, 2021 16:30 ET Company Participants Jen Robinson - Vice President, Investor Relations Steve Hoerter - President and Chief Executive Officer Dan Martin - Chief Commercial Officer Matt Sherman - Chief Medical Offic...
- Second Quarter 2021 QINLOCK® Net Product Revenue of $22.0 Million - - Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line Gastrointestinal Stromal Tumor (GIST) Expected in the Fourth Quarter of 2021 - - First Patient Treated in P...
AFG, AIZ, AKAM, AMGN, APAM, ATVI, AYX, BKH, BLKB, BNFT, CAR, CDLX, COUR, CW, CZR, DCPH, DEI, DENN, DK, DVA, DVN, ET, EVTC, FICO, FMC, FNF, FRG, GBT, GDOT, H, HPP, HST, ICFI, ICHR, INFN, INSP, IOSP, JAZZ, KAI, KAR, KFRC, KTOS, KWR, LPSN, LSCC, LSI, LYFT, LYV, MANT, MGRC, MRCY, MTCH, MYGN, NBIX...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 P...
Biotech stock investing is full of ups and downs. Anyone who's been watching ChemoCentryx (NASDAQ: CCXI) and Deciphera Pharmaceuticals (NASDAQ: DCPH) lately can tell you all about the downs. Shares of ChemoCentryx were soaring in 2020 until an FDA advisory committee vote...
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...
– Phase 1 Study will Assess First-in-Class Switch-control ULK Kinase Inhibitor Designed to Inhibit Autophagy as a Single Agent and in Combination with a MEK Inhibitor – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...